Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs

Published:2021-04 Issue:4 Volume:42 Page:128-136
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm Drug Dispos

Author:

Williamson Beth¹^ORCID,Pilla Reddy Venkatesh²³^ORCID

Affiliation:

1. Drug Metabolism and Pharmacokinetics Early Oncology Oncology R&D AstraZeneca Cambridge UK

2. Modelling and Simulation, Early Oncology Oncology R&D AstraZeneca Cambridge UK

3. Clinical Pharmacology and Quantitative Pharmacology Biopharmaceuticals R&D AstraZeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bdd.2276

Reference62 articles.

1. A comprehensive insight on ocular pharmacokinetics

2. Alectinib NDA. (2015). Retrieved fromhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf

3. Kinase-targeted cancer therapies: progress, challenges and future directions

4. The clearance of dead cells by efferocytosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy;Progress in Retinal and Eye Research;2024-03

2. Recent advances of smart materials for ocular drug delivery;Advanced Drug Delivery Reviews;2023-09

3. PEGylation of anti-MerTK Antibody Modulates Ocular Biodistribution;Bioconjugate Chemistry;2022-09-25

4. Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment;Archives of Toxicology;2022-01-01

5. ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure;Frontiers in Pharmacology;2021-06-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3